Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
Liver Int 31(5):667-75 (2011) PMID 21040410
Telbivudine showed greater antiviral suppression than lamivudine in phase II and III clinical trials. Aims: The present phase IIIb, randomized, double-blind, multicentre global trial assessed the antiviral efficacy and safety of telbivudine switch in chronic hepatitis B (CHB) patients who exhibited persistent viraemia under lamivudine therapy.
DOI: 10.1111/j.1478-3231.2010.02360.x
Version: za2963e q8zae q8zbf q8zc4 q8zda q8ze0 q8zff q8zg4